Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. https://doi.org/10.1016/j.diabres.2018.02.023.

Article  CAS  PubMed  Google Scholar 

Ma RCW. Epidemiology of diabetes and diabetic complications in China. Diabetologia. 2018;61(6):1249–60. https://doi.org/10.1007/s00125-018-4557-7.

Article  PubMed  Google Scholar 

Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53. https://doi.org/10.1038/nm.2307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peddinti G, Cobb J, Yengo L, Froguel P, Kravić J, Balkau B, et al. Early metabolic markers identify potential targets for the prevention of type 2 diabetes. Diabetologia. 2017;60(9):1740–50. https://doi.org/10.1007/s00125-017-4325-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim EJ, Ramachandran R, Wierzbicki AS. Lipidomics in diabetes. CurrOpin Endocrinol Diabetes Obes. 2022;29(2):124–30. https://doi.org/10.1097/MED.0000000000000704.

Article  CAS  Google Scholar 

Lu J, Lam SM, Wan Q, Shi L, Huo Y, Chen L, et al. High-coverage targeted lipidomics reveals novel serum lipid predictors and lipid pathway dysregulation antecedent to type 2 diabetes onset in normoglycemic Chinese adults. Diabetes Care. 2019;42(11):2117–26. https://doi.org/10.2337/dc19-0100.

Article  CAS  PubMed  Google Scholar 

Lu Y, Wang Y, Ong CN, Subramaniam T, Choi HW, Yuan JM, et al. Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS. Diabetologia. 2016;59(11):2349–59. https://doi.org/10.1007/s00125-016-4069-2.

Article  CAS  PubMed  Google Scholar 

Chen S, Zong G, Wu Q, Yun H, Niu Z, Zheng H, et al. Associations of plasma glycerophospholipid profile with modifiable lifestyles and incident diabetes in middle-aged and older Chinese. Diabetologia. 2022;65(2):315–28. https://doi.org/10.1007/s00125-021-05611-3.

Article  CAS  PubMed  Google Scholar 

Tsimihodimos V, Elisaf M. Incretins and lipid metabolism. Curr Med Chem. 2018;25(18):2133–9. https://doi.org/10.2174/0929867324666170414164244.

Article  CAS  PubMed  Google Scholar 

Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes ObesMetab. 2015;17(10):974–83. https://doi.org/10.1111/dom.

Article  CAS  Google Scholar 

Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycatedhaemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes ObesMetab. 2016;18(3):249–57. https://doi.org/10.1111/dom.12602.

Article  CAS  Google Scholar 

Sun F, Wu S, Wang J, Guo S, Chai S, Yang Z, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225-241.e8. https://doi.org/10.1016/j.clinthera.2014.11.008.

Article  CAS  PubMed  Google Scholar 

Zhang L, Hu Y, An Y, Wang Q, Liu J, Wang G. The changes of lipidomic profiles reveal therapeutic effects of exenatide in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022;13:677202. https://doi.org/10.3389/fendo.2022.677202.

Article  PubMed  Google Scholar 

Nygren H, Seppänen-Laakso T, Castillo S, Hyötyläinen T, Orešič M. Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. Methods Mol Biol. 2011;708:247–57. https://doi.org/10.1007/978-1-61737-985-7_15.

Article  CAS  PubMed  Google Scholar 

Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39(5):833–46. https://doi.org/10.2337/dc15-2251.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arneth B, Arneth R, Shams M. Metabolomics of type 1 and type 2 diabetes. Int J Mol Sci. 2019;20(10):2467. https://doi.org/10.3390/ijms20102467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121(4):1402–11. https://doi.org/10.1172/JCI44442.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suvitaival T, Bondia-Pons I, Yetukuri L, Pöhö P, Nolan JJ, Hyötyläinen T, et al. Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men. Metabolism. 2018;78:1–12. https://doi.org/10.1016/j.metabol.2017.08.014.

Article  CAS  PubMed  Google Scholar 

Wong G, Barlow CK, Weir JM, Jowett JB, Magliano DJ, Zimmet P, et al. Inclusion of plasma lipid species improves classification of individuals at risk of type 2 diabetes. PLoSOne. 2013;8(10):e76577. https://doi.org/10.1371/journal.pone.0076577.

Article  CAS  Google Scholar 

Ståhlman M, Pham HT, Adiels M, Mitchell TW, Blanksby SJ, Fagerberg B, et al. Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes. Diabetologia. 2012;55(4):1156–66. https://doi.org/10.1007/s00125-011-2444-6.

Article  CAS  PubMed  Google Scholar 

Prada M, Wittenbecher C, Eichelmann F, Wernitz A, Drouin-Chartier JP, Schulze MB. Association of the odd-chain fatty acid content in lipid groups with type 2 diabetes risk: a targeted analysis of lipidomics data in the EPIC-Potsdam cohort. Clin Nutr. 2021;40(8):4988–99. https://doi.org/10.1016/j.clnu.2021.06.006.

Article  CAS  PubMed  Google Scholar 

Zhao X, Fritsche J, Wang J, Chen J, Rittig K, Schmitt-Kopplin P, et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics. 2010;6(3):362–74. https://doi.org/10.1007/s11306-010-0203-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tonks KT, Coster AC, Christopher MJ, Chaudhuri R, Xu A, Gagnon-Bartsch J, et al. Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans. Obesity (Silver Spring). 2016;24(4):908–16. https://doi.org/10.1002/oby.21448.

Article  CAS  PubMed  Google Scholar 

Razquin C, Toledo E, Clish CB, Ruiz-Canela M, Dennis C, Corella D, et al. Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial. Diabetes Care. 2018;41(12):2617–24. https://doi.org/10.2337/dc18-0840.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892.

Article  CAS  PubMed  Google Scholar 

Kuwata H, Yabe D, Murotani K, Fujiwara Y, Haraguchi T, Kubota S, et al. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: a prospective, observational study. J Diabetes Investig. 2021;12(12):2162–71. https://doi.org/10.1111/jdi.13598.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu Z, Wu Q, Sun L, Qi Q, Zheng H, Li H, et al. Circulating glycerolipids, fatty liver index, and incidence of type 2 diabetes: a prospective study among Chinese. J Clin Endocrinol Metab. 2021;106(7):2010–20. https://doi.org/10.1210/clinem/dgab165.